FAIRFIELD, Conn., March 22, 2004 (PRIMEZONE) -- Competitive Technologies, Inc. (AMEX:CTT) today announced the appointment of two new members to its commercialization team: Dr. Michael Kiley as Vice President, Digital Business Development, and Dr. Jaen Andrews as Associate General Counsel and Senior Patent Counsel.
Dr. Kiley brings to CTT over 20 years of program management experience with the US Navy. Recently, while on active and post-Navy assignment, he was at the Office of Naval Research where he directed multi-disciplinary research teams in the areas of condition-based maintenance, cost-reduction technologies and building partnerships to effect technology transition. These programs involved commercial partners ranging from Fortune 100 companies to privately-held small businesses on the industry side, and numerous colleges and universities on the academic side. Prior to retiring in 2000, Dr. Kiley served in various R&D, headquarters and flying assignments, compiling over 5,000 flight hours and completing over 50 combat missions. While assigned to the staff of the Chief of Naval Operations, Dr. Kiley's responsibilities included outsourcing, force structure and business process reengineering.
Dr. Kiley holds a BA in Economics and an MA in Economics and Political Science from Boston College, and a PhD in Econometrics from Boston University.
Dr. Andrews brings to CTT legal and technical credentials with over 10 years of experience in intellectual property in private practice and in industry, and over 20 years experience as a research scientist. At CTT Dr. Andrews will be responsible for patent preparation and prosecution, patent portfolio and technology evaluations, and related licensing activities for key life science technologies. In addition, she will be responsible for agreement drafting, infrastructure support and corporate legal matters. Dr. Andrews' practice of intellectual property law is solidly grounded in her wide expertise in all areas of biotechnology, including both animal and plant sciences, and spans areas from biochemistry, physiology and cell biology to molecular genetics and genetic engineering, from pharmacology to medical diagnosis and treatment, and from transgenic plants to traditional plant breeding. Her expertise is based in part upon her extensive basic and applied research experience in both academic and industrial facilities in the US and abroad.
Dr. Andrews holds a BS from Cornell University, and a PhD and a JD from the University of Wisconsin-Madison. As a scientist, she was awarded an Alexander von Humboldt Fellowship and lived in Germany for two years. As an attorney, Dr. Andrews is admitted to practice in Wisconsin and before the US District Court for the Western District of Wisconsin, as well as before the US Patent and Trademark Office.
"The relationships, experience and training of these two individuals add impressive credentials to our commercialization team. We are pleased to have them as part of our organization," said John B. Nano, CTT's President and CEO. "They will join a group that is aggressively marketing and growing our portfolio of technologies including nanotechnology bone biomaterial, an anti-cancer/anti-angiogenic compound, wound sealant, an enterovirus assay, language-mastering software, silicon carbide wafer testing, specialty chemicals, fuel additives, pollution abatement and automotive safety sensors. Our team is creating solid relationships with both customers and clients, forming strategic global alliances and strengthening shareholder value."
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, digital, nano, and physical sciences developed by universities, companies and inventors. The global market for technology transfer services is estimated at $150 billion annually. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: http://www.competitivetech.net
Statements about the Company's future expectations, including development and regulatory plans, and all other statements in this document other than historical facts are "forward-looking statements" within the meaning of applicable Federal Securities Laws and are not guarantees of future performance. These statements involve risks and uncertainties, including those set forth in Item 1 of the Company's most recent Form 10-K and in CTT's other filings with the SEC, and are subject to change at any time. The Company's actual results could differ materially from these forward-looking statements. The Company undertakes no obligation to update publicly any forward-looking statement.